A link between reproductive hormones and melanoma has long been suspected, and has been examined for numerous hormonal exposures, but the association between in-vitro fertilization (IVF) and melanoma has not been studied in depth. We used whole-population linked hospital and registry data to carry out a cohort study of women aged 20-44 years seeking hospital investigation and treatment for infertility in Western Australia from 1982 to 2002 with follow-up to 2010. The cohort comprised a total of 21 604 women followed for an average of 17.2 years. Of these, 7524 had IVF treatment, 14 870 gave birth and 149 women were diagnosed with an incident invasive melanoma. Using Cox regression analysis, we estimated hazard ratios (HRs) for melanoma associated with IVF and parity. Women who had IVF and gave birth had an increased rate of invasive melanoma compared with women who had IVF and remained nulliparous (HR 3.61; 95% confidence interval 1.79-7.26). There was little or no increase in the rate of invasive melanoma associated with giving birth in women who had non-IVF infertility treatment (HR 1.39; 95% confidence interval 0.88-2.20). These results suggest an association between reproductive factors and melanoma in the subgroup of women undergoing IVF treatment.
Introduction
Circumstantial evidence suggests a link between reproductive hormones and melanoma. Age-specific melanoma incidence rates increase in women until the time of menopause, and then they slow; in men, rates continue to rise [1] . Melanocytes are hormonally responsive: pregnant women and women taking the oral contraceptive pill often develop hyperpigmentation of the skin, whereas oestrogen has been shown to stimulate melanocytes in animal experiments [2] . Furthermore, oestrogen receptors have been identified in the skin [3, 4] , in melanocytic nevi and in melanoma cells [5, 6] .
Yet, supportive evidence from epidemiological studies has remained elusive. Results from studies examining the association between pregnancy and melanoma are inconclusive. There does not appear to be an overall association between giving birth and risk of melanoma [7, 8] , although there may be a protective effect of either increasing parity or earlier age at first birth [7] [8] [9] [10] . Whether this is because of hormonal, lifestyle or socioeconomic factors remains open to question [10, 11] .
Oral contraceptive use has been associated with an increased risk of melanoma in some studies, but not in others. Feskanich et al. [12] , using data from the Nurses'
Health Study, and Koomen et al. [13] , using linked data from Holland, found an increased melanoma risk with oral contraceptive use. In contrast, early results from our own research group [14] , two meta-analyses [10, 15] and a pooled analysis of case-control studies [16] found no evidence for an association between the two. With respect to hormone replacement therapy, findings have been mixed, but overall evidence suggests a weak association or none at all [10] .
A number of studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] have examined the association between fertility drug use and melanoma. Most had only small numbers of melanoma cases and most found no association between the two. Of the two larger studies, one, with a total of 42 cases, found an increased risk with clomiphene use in nulliparous women [26] , and the other, with 112 cases, found an increased risk with specific fertility drugs in parous women [21] . The only study that directly addressed in-vitro fertilization (IVF) was carried out in Australia [25] , but this was limited in terms of having only 16 cases of melanoma in the cohort.
The aim of the present study was to examine the association between IVF treatment, parity and melanoma in a large cohort of women within a high-incidence population, also considering age at first birth, country of birth, cause of infertility, socioeconomic status, age and calendar year.
Materials and methods
The study cohort and data sources This was a whole-population cohort study using routinely collected, de-identified administrative health data serving an entire, geographically circumscribed Australian State.
Methods for identifying the study cohort have been described previously [27] [28] [29] . In summary, using the resources of the Western Australian Data Linkage System [30, 31] , we identified a cohort of women living in Western Australia (WA) undergoing hospital investigation or treatment for infertility. Women were eligible for inclusion in the cohort if they had a hospital admission with a diagnosis of either infertility or procreative management (ICD-9 628.0-628.9; ICD-10 N97.0-N97.9 or ICD-9 V26.1-V26.9; ICD-10 Z31.1-Z31.9), with their first diagnosis occurring within the period 1982-2002, when they were aged between 20 and 44 years (inclusive). Loss to follow-up was limited by excluding women known to be living outside WA or known to have moved interstate. Women who had a diagnosis of melanoma either before or within 6 months of their first hospital infertility admission were deemed not to be at risk of incident melanoma after the start of infertility treatment and were excluded.
We identified relevant exposures and outcomes occurring between 1980 and 2010, linking de-identified data sourced from the WA Hospital Morbidity Data System, the Midwives Notification System, the WA Cancer Registry, the WA Deaths Register, the Reproductive Technology Register and the WA Electoral Roll. The principal exposure was IVF treatment (including both IVF and intracytoplasmic sperm injection). IVF cycles undertaken between 1982 and 2002 were identified from either the Reproductive Technology Register, which provided information on IVF cycles from 1993 to 2002, or the Hospital Morbidity Data System. Births occurring before and after recruitment into the cohort were identified from the Midwives Notification System, a statutory data collection that captures all births in WA. Socioeconomic status was obtained from the address recorded on the woman's hospital record at the start of follow-up. Two measures of socioeconomic status were estimated: the Index of Economic Resources and the Index of Education and Occupation [32] . Country of birth may influence melanoma risk through its association with skin type, cultural attitudes towards sun exposure and childhood sun exposure. Information on country of birth was extracted from each woman's hospital records, aggregated into broad geographical regions and included as a potential confounder in regression analyses.
We considered two sets of outcomes. The first was an incident diagnosis of invasive cutaneous melanoma only (ICD-10: C43.0-C43.9) and the second was any incident diagnosis of melanoma: invasive or in-situ cutaneous melanoma (ICD-10: C43.0-C43.9 or ICD-10: D03.0-D03.9). Both were identified through data linkage to records of the WA Cancer Registry. Results for both outcomes are presented in this paper; we present detailed results for the analysis of invasive melanoma alone and summary results for the analysis of invasive or in-situ melanoma.
Data analysis
Data were analysed and hazard ratios (HRs) were estimated using Cox regression analysis. We used methods described by Hosmer et al. [33] to develop the regression model. Women were followed from their first infertility-related hospital admission to the date of melanoma diagnosis, date of death or censor date (15 August 2010), whichever came first. Events that could occur after the start of follow-up (births, start of IVF treatment) were entered into the model as timedependent covariates; events that were measured at the start of follow-up (age, calendar year, country of birth, infertility diagnosis and socioeconomic status) were entered as fixed covariates. Age was grouped into quartiles and included in the model as a categorical variable. Birth (yes/no), age group at first birth (< 25; 25-30; 30-35 and Z 35 years) and parity (0, 1, 2 or Z 3 births) were examined as categorical variables in separate models. Socioeconomic status was included as a binary categorical variable, with women in the upper quartile of each index compared with women in the lower three quartiles combined. Country of birth and infertility diagnosis were included as categorical variables.
We investigated the interaction between birth and IVF and considered the association between birth and melanoma separately in women who did and did not have IVF and the association between IVF and melanoma separately in women who did and did not give birth.
We also considered the effect of birth before IVF as distinct from the effect of birth after IVF. Some women in our cohort only gave birth before IVF (they had secondary infertility and the treatment was unsuccessful); some only gave birth after IVF (women with primary infertility and successful treatment) and others gave birth both before and after IVF. To examine the separate effects of giving birth before IVF and giving birth after IVF, we restricted the cohort in this additional analysis to women with a maximum of one birth. We compared the rate of invasive melanoma in women who did not give birth with women who only gave birth before IVF and women who only gave birth after IVF. and the Department of Health WA Human Research Ethics Committee.
Results
The study cohort
The study cohort was drawn from an eligible population of 22 040 women. We excluded 379 women known to be living outside WA, leaving 21 661 women. We considered two separate outcomes in this study: an incident diagnosis of invasive cutaneous melanoma and any incident diagnosis of melanoma: either invasive cutaneous melanoma or cutaneous melanoma in situ. Because these were two separate outcomes, with different endpoints and different follow-up times, we developed two separate datasets. For the study of invasive melanoma only, we excluded 57 women who had an invasive melanoma either before or within 6 months of the start of follow-up, leaving a total of 21 604 women under study. For the second data set, we excluded 59 women with invasive or in-situ melanoma, leaving a total of 21 602 women under study.
The results for the invasive melanoma analysis, which was the focus of this paper, are reported in Tables 1-3 and in the accompanying description. The results for the invasive or in-situ analysis appear at the end of the results section in summary form under the heading 'Type of melanoma: invasive melanoma or melanoma in situ'.
The total duration of follow-up was 370 695 person-years. Women were followed for an average of 17.2 years, from entry into the cohort at a mean age of 31.2 years to the end of follow-up, when they were, on average, 48.3 years old. During this time, 149 out of a total of 21 604 women were diagnosed with an incident invasive melanoma. Of these, 4861 women had IVF and gave birth (45 diagnosed with invasive melanoma); 2663 had IVF and remained nulliparous (10 melanoma diagnoses). Of those who did not have IVF, 10 009 were parous (67 melanoma cases) and 4071 remained nulliparous (27 melanoma cases). The average age at melanoma diagnosis was 42.0 years (Table 1) . Women were diagnosed with an invasive melanoma on average 10.5±6.3 years (median 10.1 years) after entry into the cohort. Women undergoing IVF were diagnosed 9.7±5.7 years (median 8.9 years) after their first cycle and 8.9±5.8 years (median 8.6 years) after their last cycle.
Women gave birth to their first child, either before or after entry into the cohort, at an average age of 29.6 years ( Table 1) .
Women undergoing IVF were older at the birth of their first child (average age 32.2 years). They were mostly of lower parity, with a median of one child (Table 1 ). They were generally of higher socioeconomic status at cohort entry and more likely to be in the upper quartile of both the Index of Education and Occupation and the Index of Economic Resources (Table 1) .
Most (n = 14 109; 65.3%) of the women in the cohort were born in Australia; of these, 682 identified as being of Aboriginal or Torres Strait Islander descent. Among those born overseas, 3410 were from the UK, with smaller numbers migrating from North Africa (n = 1094), the Pacific Islands (n = 760), Europe (n = 676) and Asia (n = 667).
Association between in-vitro fertilization, potential confounders and invasive melanoma: Cox regression analysis
We examined the association between invasive melanoma and a number of factors, first in univariate analysis and then in separate age-adjusted analyses ( Table 2 ).
We did not find an association between IVF treatment and invasive melanoma, with an age-adjusted HR of 1.16 [95% confidence interval (CI) 0.83-1.62] ( Table 2) .
We did, however, find an increased rate of invasive melanoma in women who gave birth, compared with women who remained nulliparous (HR = 1.97; 95% CI 1.34-2.88). There was no clear trend with increasing age at first birth, although the relative risk appeared greatest in women who delivered their first child when they were 35 years of age or older (HR = 2.32) ( Table 2) . Women who delivered one or two children had an increased rate of invasive melanoma compared with nulliparous women; the HR for women who delivered two children was 2.24. The rate in women delivering three or more children was lower (HR 1.37; 95% CI 0.81-2.31) ( Table 2) .
We considered the possible association between cause of infertility and invasive melanoma. In our cohort, 2971 women had a diagnosis of endometriosis at cohort entry and 3882 women had a diagnosis of pelvic inflammatory disease (PID) ( Table 1) . Neither diagnosis was associated with an increased rate of invasive melanoma. The HR associated with a diagnosis of endometriosis was 0.95 (95% CI 0.56-1.60) and the HR associated with a diagnosis of PID was 1.08 (95% CI 0.71-1.65) ( Table 2 ).
There was no evidence for an association between melanoma and socioeconomic status in this group of women. Those in the upper quartiles of the Index of Economic Resources and the Index of Education and Occupation appeared to have the same rate of melanoma as women in the lower three quartiles combined.
We found no evidence for an increase in invasive melanoma rate with calendar time in this cohort ( Table 2) .
We examined the interaction between IVF treatment and birth, and found evidence for effect modification. We therefore present results separately for women who had IVF and women who did not ( Table 3 , and described below) and women who gave birth and women who did not (described below). Among women who had IVF, there was a clear increase in the rate of invasive melanoma in women who gave birth, compared with those who remained nulliparous (HR 3.61; 95% CI 1.79-7.26) (Table 3) , particularly among women who gave birth to two children (HR 4.29; 95% CI 1.97-9.34). In contrast, among women who had infertility treatment but not IVF, there was only a small increase in the rate of invasive melanoma in women who gave birth and CIs included 1 (HR 1.39; 95% CI 0.88-2.20) (Table 3 ). There did not appear to be any association with either increasing parity or age at first birth in this group of women.
We found no evidence for an association between IVF treatment and invasive melanoma among women who remained nulliparous (HR = 0.63; 95% CI 0.30-1.31), but some evidence for an association with IVF treatment among parous women (HR = 1.45; 95% CI 0.99-2.13).
We included country of birth as a potential confounder in the relationship between IVF, birth and invasive melanoma. HRs derived from models that included country of birth varied little from those that did not include this variable, suggesting that country of birth was not a confounder in the relationship between IVF, birth and invasive melanoma. For example, the age-adjusted HR for IVF in the entire cohort was 1.16; inclusion of country of birth in the model resulted in an HR estimate of 1.11. The age-adjusted estimate for birth among women undergoing IVF treatment was 3.61; after adjustment for country of birth, it was 3.47 (see also footnotes to Tables 2 and 3 ).
Dose-response effect
Women in our cohort generally underwent only a small number of IVF cycles (median = 2). It was therefore not possible to examine the effect of IVF 'dose' in detail. However, we compared the association between IVF treatment and invasive melanoma in women who had one cycle with women who had two or more cycles. We found no evidence for an increased rate of invasive melanoma in women who had two or more cycles compared with The study population included all women in Western Australia commencing hospital investigation or treatment for infertility between 1982 and 2002. We excluded women with a diagnosis of invasive melanoma either before or within 6 months of their first infertility admission. b Infertility diagnoses of endometriosis or PID were included in the women's hospital records at or before entry into the cohort. c All means are expressed as ±SD. HRs are estimated from separate models that include only age at the start of follow-up and the listed variable. b Further adjustment by country of birth yielded estimates that were only slightly different from the above. The HR for in-vitro fertilization (IVF) after adjustment for age and country of birth was 1.11 (95% CI 0.79-1.55), suggesting that country of birth did not confound the relationship between IVF and melanoma rate in this analysis.
women who had only one cycle, with an HR of 1.04 (95% CI 0.60-1.81) after adjustment for age and birth.
Birth before in-vitro fertilization versus birth after in-vitro fertilization For this analysis, to examine the association between timing of birth (before IVF treatment vs. after IVF treatment) and invasive melanoma, we restricted the cohort to women with a maximum of one birth. In this subset of 4539 women, we could thus compare three separate categories: women who did not give birth, women who only gave birth before IVF and women who only gave birth after IVF. In age-adjusted analysis, the HR for invasive melanoma associated with giving birth before IVF was 4.17 (95% CI 1.13-15.49) and the HR associated with giving birth after IVF was 3.60 (1.51-8.59).
Incidence rates
We also calculated crude incidence rates (number of invasive melanoma cases/total person-years of follow-up). For women having IVF and remaining nulliparous, the crude incidence rate was 20.6 cases/100 000 person-years; for women having IVF and giving birth it was 57.1. For women having infertility treatment, but not IVF, and remaining nulliparous it was 37.0 cases/100 000 personyears; for women having infertility treatment but not IVF and giving birth it was 39.3. Note that these are crude estimates: they are not adjusted for age and, for women who gave birth, they do not take into account the portion of follow-up time before the first birth when women were correctly classified, in the regression analysis, as nulliparous.
Type of melanoma: invasive melanoma or melanoma in situ
A total of 235 women in the cohort had an incident diagnosis of either invasive or in-situ melanoma. The results from the analysis that considered either diagnosis as an endpoint: invasive or in-situ melanoma, were similar to those from the analysis that only included invasive melanoma, except that generally, the HRs observed were smaller. As in the invasive melanoma analysis, we found no evidence for an association between IVF treatment and melanoma (HR = 1.04; 95% CI 0.79-1.36). There was little evidence for an association with birth among women who did not have IVF, with an overall HR for the outcome of invasive or in-situ melanoma of 1.29 (95% CI 0.90-1.84). The association between birth and melanoma among women who had IVF followed a pattern similar to the results presented in Table 3 for the invasive melanoma analysis, except that in all cases, the magnitude of the relative risk was smaller. Among women who had IVF, there was an increased rate of invasive melanoma or melanoma in situ in women who gave birth compared with women who remained nulliparous (HR 1.83; 95% CI 1.13-2.97).
Discussion
The results of this study show that among women in our cohort who had IVF treatment, giving birth was associated with a 3.6-fold increase in the rate of invasive melanoma. In contrast, in women having non-IVF infertility treatment, giving birth made little or no contribution to the risk of melanoma.
This finding could be interpreted in a number of ways. The first possibility is that a causal relationship exists: exposure to both IVF treatment and birth are necessary for the risk of melanoma to be increased. However, arguing against this is, first, the absence of a doseresponse relationship: women who had two or more cycles of IVF were not at increased risk of melanoma compared with women who had only one, and second, our observation that the order in which birth or IVF occurred did not seem to matter: the rate of melanoma was elevated in women who gave birth before IVF treatment as well as in women who gave birth after IVF treatment.
A second possible explanation for this finding is that women undergoing IVF share a common predisposition to melanoma that is promoted by the hormonal environment surrounding pregnancy, birth and lactation. A third alternative is that this finding is because of confounding by unmeasured confounders, in particular, known melanoma risk factors including sun exposure, sunburn history and skin complexion [34] [35] [36] [37] [38] [39] [40] . In an attempt to address this problem, we included country of birth in the Table 3 Age-adjusted Cox regression analysis: estimated hazard ratios for birth, age at first birth and parity in women exposed and not exposed to in-vitro fertilization a Exposure Age-adjusted HR (95% CI) for women not undergoing IVF Age-adjusted HR (95% CI) for women undergoing IVF
Birth
No birth recorded 1.00 1.00 Birth of one or more children regression models. Country of birth has been shown to be associated with the risk of melanoma [41] [42] [43] as it represents an aggregate measure of an individual's skin type, cultural attitudes to sun exposure and potential sun exposure during early life. We found no evidence for confounding by this variable. In addition, for these results to be explained by confounding by known melanoma risk factors related to sun exposure, we would need to assume that women who had IVF and gave birth were more likely to have fair skin or were more likely to have a history of sunburn than women who had IVF and remained childless. This explanation seems less plausible than an explanation based on hormonal factors [44] . It is also possible that this is simply a chance finding, although one other group [21] found that exposure to fertility drugs commonly used in IVF (follicle-stimulating hormone, human menopausal gonadotropin and gonadotropin-releasing hormone) was associated with a two-to three-fold increase in the risk of melanoma in parous but not nulliparous women.
It is unlikely that this observed increase in melanoma rate was because of detection bias. Increased surveillance is likely to lead to earlier detection and hence more in-situ cancers. If detection bias was the explanation, we would expect to find greater relative risks in the analysis that included both invasive and in-situ melanomas, whereas we actually found lower relative risks in this analysis.
We also considered a number of other potential melanoma risk factors. We did not find an association between socioeconomic status and melanoma. This finding was consistent with an Australian national survey [1] , but not with a US National survey, where high socioeconomic status was found to be associated with an increased rate of melanoma [45] . There was no evidence for an association with the most common infertility diagnoses in our cohort: endometriosis and PID. There did not appear to be an association between increasing parity or age at first birth and melanoma in women in our cohort having infertility treatment but not IVF, and no clear pattern among women who had IVF. Previous studies have identified a decreased risk with parity greater than 5 and first birth before age 20 [7] , but both of these groups made up only a very small proportion of our infertility cohort.
The main limitation of our study was a lack of information on known melanoma risk factors, including skin type and sun exposure. We attempted to address this by including country of birth in our regression models, although we recognize that this variable may not accurately represent a woman's underlying melanoma risk related to sun exposure. In addition, we had no information on the use of fertility drugs other than those associated with an IVF cycle: women in both the IVF and the non-IVF group may have been treated with such fertility drugs. However, the levels of circulating hormones developed after fertility drug treatment are much lower than after IVF as the objective of fertility drug treatment is generally to induce ovulation, whereas the objective of IVF treatment is to induce superovulation; hence, the hormone levels achieved would be much greater.
Although it is important that the findings of this study are replicated in future research, they are, nevertheless, noteworthy because they show an association between reproductive factors and melanoma in women undergoing IVF treatment. In practical terms, it may be advisable for women who have IVF treatment and give birth to be made aware of the importance of checking for changes in their skin and seeking early treatment.
